IDEXX Laboratories, Inc. vs Under Armour Inc Class A — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Under Armour Inc Class A trades at $5.29 (market cap $2.26B). The key difference: IDEXX Laboratories, Inc. is far larger — about 20.5× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | UAA | |
|---|---|---|
Market Cap | $46.22B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $8.14 |
52-Week Low | $526.44 | $4.17 |
Enterprise Value | $47.12B | $3.24B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Under Armour (UAA) is trading at $5.245, down 10.49% today, reflecting ongoing challenges with revenue declines and negative profitability. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a net loss of -$201.27M in 2025 and negative cash flow trends. Recent Q1 2027 earnings beat expectations but revealed weaker revenue and cautious guidance, with management maintaining profitability outlook despite sales headwinds.
The outlook remains challenging with declining revenues and negative margins, though current valuation metrics appear reasonable. Key risks include weak North American demand and competitive pressures, while potential catalysts include new product collaborations and cost management. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →